Skip to main content
Alex Johs at ORNL's Spallation Neutron Source

Sometimes solutions to the biggest problems can be found in the smallest details. The work of biochemist Alex Johs at Oak Ridge National Laboratory bears this out, as he focuses on understanding protein structures and molecular interactions to resolve complex global problems like the spread of mercury pollution in waterways and the food supply.

Quantum—Widening the net

Scientists at Oak Ridge National Laboratory studying quantum communications have discovered a more practical way to share secret messages among three parties, which could ultimately lead to better cybersecurity for the electric grid 

Virtual universes

Using Summit, the world’s most powerful supercomputer housed at Oak Ridge National Laboratory, a team led by Argonne National Laboratory ran three of the largest cosmological simulations known to date.

Small modular reactor computer simulation

In a step toward advancing small modular nuclear reactor designs, scientists at Oak Ridge National Laboratory have run reactor simulations on ORNL supercomputer Summit with greater-than-expected computational efficiency.

Low-cost, compact, printed sensor that can collect and transmit data on electrical appliances for better load monitoring

Scientists at Oak Ridge National Laboratory have developed a low-cost, printed, flexible sensor that can wrap around power cables to precisely monitor electrical loads from household appliances to support grid operations.

 

Desalination diagram

A team of scientists led by Oak Ridge National Laboratory used carbon nanotubes to improve a desalination process that attracts and removes ionic compounds such as salt from water using charged electrodes.

Illustration of the intricate organization of the PKA structure, wherein different parts of the protein are connected through elaborate hydrogen bonding networks (dashed yellow lines), glued together by the hydrophobic assemblies (light blue and orange volumes)—all working together to build the functional active site. Insert shows protonation of the transferred phosphoryl group (cyan mesh) and its many interactions with water and the active site amino acid residues. Credit: Jill Hemman/ORNL

OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.

ORNL-led collaboration solves a beta-decay puzzle with advanced nuclear models

OAK RIDGE, Tenn., March 11, 2019—An international collaboration including scientists at the Department of Energy’s Oak Ridge National Laboratory solved a 50-year-old puzzle that explains why beta decays of atomic nuclei 

Neutron scattering allowed direct observation of how aurein induces lateral segregation in the bacteria membranes, which creates instability in the membrane structure. This instability causes the membranes to fail, making harmful bacteria less effective.

As the rise of antibiotic-resistant bacteria known as superbugs threatens public health, Oak Ridge National Laboratory’s Shuo Qian and Veerendra Sharma from the Bhaba Atomic Research Centre in India are using neutron scattering to study how an antibacterial peptide interacts with and fights harmful bacteria.

(From left) ORNL Associate Laboratory Director for Computing and Computational Sciences Jeff Nichols; ORNL Health Data Sciences Institute Director Gina Tourassi; DOE Deputy Under Secretary for Science Thomas Cubbage; ORNL Task Lead for Biostatistics Blair Christian; and ORNL Research Scientist Ioana Danciu were invited to the White House to showcase an ORNL-developed digital tool aimed at better matching cancer patients with clinical trials.

OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.